Merck & Co., Inc. $MRK Stock Position Lessened by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 7.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,229,793 shares of the company’s stock after selling 624,383 shares during the period. Alliancebernstein L.P. owned approximately 0.33% of Merck & Co., Inc. worth $690,727,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ameriprise Financial Inc. boosted its holdings in shares of Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares in the last quarter. Ashford Capital Management Inc. raised its holdings in Merck & Co., Inc. by 45.3% during the third quarter. Ashford Capital Management Inc. now owns 26,683 shares of the company’s stock worth $2,240,000 after purchasing an additional 8,321 shares in the last quarter. Creative Planning raised its holdings in Merck & Co., Inc. by 14.0% during the third quarter. Creative Planning now owns 1,076,508 shares of the company’s stock worth $90,351,000 after purchasing an additional 131,857 shares in the last quarter. New England Asset Management Inc. lifted its position in Merck & Co., Inc. by 25.7% in the third quarter. New England Asset Management Inc. now owns 65,550 shares of the company’s stock worth $5,502,000 after purchasing an additional 13,400 shares during the period. Finally, Lazard Asset Management LLC lifted its position in Merck & Co., Inc. by 6.9% in the third quarter. Lazard Asset Management LLC now owns 7,063,672 shares of the company’s stock worth $592,854,000 after purchasing an additional 454,605 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Price Performance

MRK opened at $115.61 on Friday. The stock has a market cap of $285.84 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a fifty day moving average price of $115.26 and a 200 day moving average price of $99.68.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is 46.70%.

Insider Buying and Selling

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MRK. Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Cantor Fitzgerald upped their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Scotiabank raised their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research report on Thursday, December 4th. The Goldman Sachs Group increased their target price on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $126.81.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.